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The	most	significant	characteristic	feature	of	ovarian	cancer	
is	the	intraperitoneal	spread	in	its	early	occurrence.	Therefore,	
it	is	reasonable	to	consider	the	intraperitoneal	(IP)	chemother-
apy	for	this	disease	entity.	The	primary	concept	of	IP	chemo-
therapy	is	to	expose	the	tumor	tissue	directly	to	an	extremely	
high	concentration	of	anticancer	agents	by	perfusing	inside	
the	peritoneal	cavity	[1].	IP	chemotherapy	has	been	inves-
tigated	for	a	long	time,	and	there	have	actually	been	three	
large-scale	randomized	trials	conducted	in	the	US,	all	of	which	
showed	overall	and/or	progression-free	survival	benefit	[2-4].	
Based	on	these	results,	the	National	Cancer	Institute	(NCI)	and	
the	Gynecologic	Oncology	Group	(GOG)	performed	a	meta-
analysis	on	the	results	of	these	three	US	trials	and	other	phase	
III	trials	of	IP	versus	intravenous	(IV)	chemotherapy,	and	sig-
nificant	improvement	of	survival	was	shown	with	IP	therapy.	
Based	on	this	meta-analysis,	the	NCI	has	released	a	clinical	
announcement	encouraging	the	gynecological	oncology	
community	to	consider	IP	chemotherapy	using	cisplatin	as	
the	standard	treatment	for	advanced	ovarian	cancer	patients	
in	whom	the	residual	disease	were	debulked	to	1	cm	or	less	
[5].	Unfortunately,	however,	IP	chemotherapy	has	not	been	
adopted	as	a	standard	care	because	there	are	several	con-
troversial	issues	to	be	solved.	One	of	the	major	issues	to	be	
resolved	is	the	chemotherapy-related	toxicity.	Another	con-
cern	is	the	catheter-related	problems	such	as	port	infection	or	
occlusion	[4,6].	In	the	GOG	172	trial,	the	completion	rate	of	IP	
chemotherapy	for	6	cycles	was	only	42%.	Twenty-seven	per-
cent	of	them	received	either	no	IP	chemotherapy	(8%)	or	only	
one	cycle	(19%).	Despite	the	fact	that	the	majority	of	patients	
in	the	IP	arm	of	the	GOG	172	trial	did	not	complete	the	IP	che-
motherapy,	overall	survival	was	significantly	better	than	the	
IV	chemotherapy	arm.	This	raised	the	question	of	how	many	
cycles	of	IP	chemotherapy	is	needed	to	obtain	survival	advan-
tage?	
In	this	issue	of	the	Journal,	Kim	et	al.	[7]	reported	the	pre-
liminary	results	of	IP	administration	of	cisplatin	at	the	time	of	
primary	surgery	followed	by	IV	chemotherapy.	The	toxicities	
were	acceptable	as	predicted,	and	the	authors	concluded	
that	further	prospective	trials	are	warranted	based	on	this	
study.	The	most	advantageous	benefit	of	this	approach	is	that	
there	is	no	need	to	place	the	access	device	for	repeating	IP	
chemotherapy.	Also,	as	the	authors	described,	the	use	of	IP	
chemotherapy	at	the	time	of	surgery	and/or	in	the	immedi-
ate	postoperative	period	facilitates	uniform	drug	delivery	and	
may	avoid	some	of	the	complications	of	prolonged	peritoneal	
access.	
However,	it	seems	to	be	too	early	to	test	this	approach	in	a	
large	scale	comparative	trial,	because	we	do	not	know	how	
many	cycles	of	IP	chemotherapy	is	minimally	needed	to	ob-
tain	survival	advantage.	In	other	words,	only	one	cycle	may	
loose	the	survival	benefit	of	IP	chemotherapy.	In	fact,	it	has	
not	been	elucidated	why	the	GOG	172	trial	demonstrated	a	
strikingly	better	survival	in	the	IP	arm	compared	to	the	IV	arm,	
despite	the	fact	that	many	of	the	patients	in	the	IP	arm	did	not	
receive	the	complete	IP	regimen	of	chemotherapy	[4].	Until	we	
find	some	clues	as	to	the	background	mechanisms	involved	
in	IP	chemotherapy,	we	should	try	providing	IP	chemotherapy	
as	many	times	as	IV	chemotherapy	using	IP	access	devices.	
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The	major	drawback	of	IP	chemotherapy	is	that	the	IP	che-
motherapy	agent	is	cisplatin,	which	is	more	toxic	and	more	
difficult	to	manage	compared	to	carboplatin,	the	current	
standard	IV	chemotherapy	agent.	Therefore,	it	is	important	to	
explore	whether	carboplatin	may	replace	cisplatin	in	IP	che-
motherapy.	Several	studies	have	demonstrated	that	the	use	of	
carboplatin	as	IP	chemotherapy	would	be	feasible	[8-10].	
Currently,	three	large-scale	randomized	trials	are	ongoing	to	
examine	the	efficacy	of	carboplatin-based	IP	chemotherapy.	
The	simplest	study	is	the	iPocc	Trial	(GOTIC-001/JGOG-3019)	
[11].	In	this	trial,	dose-dense	weekly	paclitaxel	at	80	mg/m
2	
will	be	administered	in	combination	with	carboplatin	at	area	
under	the	curve	(AUC)	6	every	three-week	either	by	IV	or	IP.	In	
this	study,	eligible	patients	are	those	with	epithelial	ovarian	
cancer	stages	II	to	IV,	thus,	this	study	will	explore	the	potential	
of	IP	chemotherapy	in	suboptimally	treated	advanced	ovarian	
cancer,	and	not	only	for	optimally	debulked	cases.	
The	classical	concept	of	IP	chemotherapy	is	local	therapy,	
which	is	the	direct	contact	of	cancer	cells	with	anticancer	
drugs,	and	it	is	believed	that	direct	penetration	of	agents	is	
limited	to	a	few	millimeters	from	the	tumor	surface	[1].	How-
ever,	it	has	been	hypothesized	the	carboplatin	administered	
into	the	IP	cavity	is	absorbed	from	the	peritoneal	surface	
within	24	hours	and	serum	the	AUC	is	exactly	the	same	as	se-
rum	platinum	AUC	after	IV	administration,	although	platinum	
AUC	in	the	IP	cavity	was	17	times	greater	when	carboplatin	
was	given	by	the	IP	than	the	IV	route	[12].	It	has	been	demon-
strated	that	IP	carboplatin	for	suboptimal	residual	cases	was	
also	feasible	as	a	phase	II	trial	[13],	and	therefore,	the	iPocc	
Trial	is	also	challenging	this	important	scientific	question.	The	
iPocc	Trial	has	just	been	opened	to	international	study	groups	
such	as	the	Korean	Gynecologic	Oncology	Group	(KGOG)	or	
the	Arbeitsgemeinschaft	Gynaekologische	Onkologie	(AGO)	
of	Austria.	The	contracts	also	have	been	under	process	with	
individual	hospitals	in	Singapore,	Australia,	and	Spain.	The	tar-
get	accrual	is	746,	and	at	the	present	time	approximately	100	
patients	have	been	enrolled,	and	the	international	community	
is	encouraged	to	participate	in	this	important	trial.	
Another	trial	is	the	GOG	252	study.	In	this	trial,	the	control	
arm	and	one	of	the	experimental	arms	are	exactly	the	same	as	
the	iPocc	Trial,	except	that	there	is	a	combination	and	mainte-
nance	administration	of	bevacizumab.	The	GOG	incorporated	
this	strategy	based	on	the	GOG	218	trial	results.	The	GOG	252	
trial	has	a	third	arm,	which	is	the	modified	GOG	172	winner	
regimen.	In	this	arm	IV	paclitaxel	at	135	mg/m
2	on	day	1	fol-
lowed	by	IP	cisplatin	at	75	mg/m
2	on	day	2,	and	then	IP	pacli-
taxel	is	administered	on	day	8.	This	arm	also	incorporates	the	
combination	and	maintenance	of	bevacizumab.	The	GOG	252	
trial	has	completed	accrual	and	awaits	for	the	results.	
The	third	trial	is	the	OV-21/GCIG	study	lead	by	the	Canadian	
National	Cancer	Institute.	This	trial	has	a	unique	approach	to	
the	IP	chemotherapy.	All	patients	with	stages	III	patients	will	
receive	neoadjuvant	chemotherapy.	Those	patients	who	re-
spond	to	the	neoadjuvant	chemotherapy	will	receive	interval	
debulking	surgery	(IDS),	and	if	the	residual	disease	after	IDS	
becomes	the	optimal	<1	cm,	the	patient	will	be	randomized	
to	one	of	the	three	arms.	The	control	arm	is	the	combination	
of	IV	paclitaxel	at	135	mg/m
2	followed	by	IV	carboplatin	at	
AUC	5	on	day	1,	and	then	IV	paclitaxel	at	60	mg/m
2	will	be	
given	on	day	8.	The	second	arm	is	same	as	the	control	arm	
but	carboplatin	will	be	given	by	the	IP	route.	The	third	arm	is	
the	modified	GOG	172	winner	arm,	which	is	the	same	as	the	
third	arm	of	GOG	252	trial	but	in	which	bevacizumab	is	not	
given.	One	of	these	two	IP	arms	(arm	2	or	arm	3)	will	be	cho-
sen,	as	a	randomized	phase	II	manner,	and	the	winner	arm	will	
be	compared	with	the	control	arm	as	phase	the	III	trial.
These	three	trials	have	different	patient	populations	and	
different	treatment	regimens,	but	will	answer	important	ques-
tions	when	compared	between	trials.	It	is	encouraged	for	
gynecologic	oncologists	to	participate	in	one	of	these	trials	
to	resolve	the	important	IP	chemotherapy	questions	for	the	
future.
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